Lfb Biotechnologies S.A.S.U.: Tg Therapeutics, Inc Position increased

June 18, 2018 - By Ellis Scott

Investors sentiment decreased to 1.46 in Q1 2018. Its down 0.54, from 2 in 2017Q4. It is negative, as 11 investors sold TG Therapeutics, Inc. shares while 30 reduced holdings. 29 funds opened positions while 31 raised stakes. 37.47 million shares or 6.47% more from 35.20 million shares in 2017Q4 were reported.

Putnam Invs Limited Co owns 92,543 shares. Legal General Grp Public Limited Co owns 9,566 shares. Colorado-based Pub Employees Retirement Association Of Colorado has invested 0% in TG Therapeutics, Inc. (NASDAQ:TGTX). First Mercantile Trust has 0.08% invested in TG Therapeutics, Inc. (NASDAQ:TGTX). Raymond James Svcs Advsr Inc holds 139,071 shares or 0.01% of its portfolio. Highland Mngmt L P holds 0.34% in TG Therapeutics, Inc. (NASDAQ:TGTX) or 464,391 shares. 114 are held by Hanseatic Mgmt Services Incorporated. Janney Montgomery Scott Limited Liability Company holds 0% or 16,310 shares. Citigroup Inc holds 0% or 92,445 shares in its portfolio. Ghost Tree Capital Limited Liability Com accumulated 300,000 shares. State Common Retirement Fund holds 103,653 shares. Rhumbline Advisers accumulated 46,152 shares or 0% of the stock. North Star Management accumulated 21,000 shares. Hanson Mcclain, a California-based fund reported 62 shares. Willingdon Wealth Management has 0% invested in TG Therapeutics, Inc. (NASDAQ:TGTX) for 4 shares.

Since December 29, 2017, it had 0 insider purchases, and 1 insider sale for $272,051 activity.

Lfb Biotechnologies S.A.S.U. Reported increased Stake in Tg Therapeutics, Inc

Lfb Biotechnologies S.A.S.U. filed with SEC a SC 13D/A form for Tg Therapeutics, Inc. It can be found at: 000119312518195773. As reported by Lfb Biotechnologies S.A.S.U., the filler increased its stake in the stock by 34.34 % for 7,614,855 shares. Lfb Biotechnologies S.A.S.U. currently owns 9.8% of the Health Care- stock. Date of activity: May 15, 2018.

Reasons Why Lfb Biotechnologies S.A.S.U. Holds Tg Therapeutics, Inc

Item4 – Purpose of Transaction

Item 4 of Schedule13D/A is hereby amended by deleting the fourth and fifth sentences of Item 4 in their entirety and inserting the following immediately after the third paragraph of Item 4:

Page 3 of 6

CUSIP NO. 88322Q108

The Exchange Agreement contains a provision pursuant to which LFB has the right to have a representativeappointed to the Company’s board of directors. Under this provision, on November9, 2012, Dr.Yann Echelard was appointed as LFB’s representative to the Company’s board of directors. Effective May15, 2018,Dr.Echelard no longer serves as LFB’s representative to the Company’s board of directors. Previously, on April27, 2018, Dr.Echelard resigned the position of CEO of rEVO Biologics a wholly owned subsidiary of LFB. Also,effective May30, 2018, LFB irrevocably waived the obligation of the Company’s board of directors to nominate a replacement designee of LFB for election to the board. In addition, LFB no longer has the right to nominate a director to serveon the Company’s board of directors since LFB owns less than 10% of the outstanding shares of the Company’s Common Stock.

LFB will continue toevaluate its investment in the Company and expects to continue to engage in communications with, without limitation, one or more stockholders of the Company, management of the Company and/or one or more members of the Company’s board ofdirectors. LFB expects that it will, from time to time, review its investment position in the Company and may, depending on the Company’s performance and other market conditions, dispose of Common Stock either in the open market or inprivately-negotiated transactions, depending upon LFB’s evaluation of the Company’s business, prospects and financial condition, the market for the Common Stock, other opportunities available to LFB, general economic conditions, stockmarket conditions and other factors.Depending upon the factors noted above, LFB may also decide to holdall or part of its investments in the Common Stock and/or enter into derivative transactions with institutional counterparties withrespect to the Company’s securities, including the Common Stock.”

Item5 – Interest in Securities of the Issuer

Tg Therapeutics, Inc Institutional Sentiment

Filings show 83 investors own Tg Therapeutics, Inc. The ownership in Q3 2017 is high, at Infinity of the outstanding shares. This is increased by 1480894. 35125128 were owned by these investors. 11 funds opened new Tg Therapeutics, Inc stakes, 29 increased positions. There were 11 that closed positions and 22 reduced them.

2 investors had the stock in their top 10. Some are: Venbio Select Advisor Llc..

Hikari Power Ltd is an investor bullish on Tg Therapeutics, Inc, owning 160000 shares as of Q3 2017 for 0.25% of its portfolio. Peter Kolchinsky Ra Capital Management Llc owns 700000 shares or 0.75% of its portfolio. NY Bridger Management Llc have 3.76% of its portfolio for 5295044 shares. Further, Senzar Asset Management Llc reported stake worth 2.50% of its portfolio. The CA Hollencrest Securities Llc owns 12000 shares. Tg Therapeutics, Inc is 0.02% of its portfolio.

SEC Form 13D.

Analysts await TG Therapeutics, Inc. (NASDAQ:TGTX) to report earnings on August, 8. They expect $-0.55 earnings per share, down 22.22 % or $0.10 from last year’s $-0.45 per share. After $-0.59 actual earnings per share reported by TG Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -6.78 % EPS growth.

The stock increased 0.73% or $0.1 during the last trading session, reaching $13.8. About 867,228 shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 14.71% since June 19, 2017 and is uptrending. It has outperformed by 2.14% the S&P500.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $1.07 billion. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

TG Therapeutics, Inc. (NASDAQ:TGTX) Ratings Coverage

Among 3 analysts covering TG Therapeutics (NASDAQ:TGTX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics has $38.0 highest and $21.5 lowest target. $31.50’s average target is 128.26% above currents $13.8 stock price. TG Therapeutics had 6 analyst reports since January 17, 2018 according to SRatingsIntel. The stock of TG Therapeutics, Inc. (NASDAQ:TGTX) has “Buy” rating given on Wednesday, January 17 by FBR Capital. The rating was maintained by Raymond James on Thursday, April 19 with “Buy”. The rating was initiated by H.C. Wainwright on Wednesday, March 21 with “Buy”. The rating was maintained by FBR Capital on Friday, February 2 with “Buy”. The firm has “Buy” rating given on Monday, June 4 by FBR Capital. FBR Capital maintained TG Therapeutics, Inc. (NASDAQ:TGTX) on Friday, March 9 with “Buy” rating.

More notable recent TG Therapeutics, Inc. (NASDAQ:TGTX) news were published by: Nasdaq.com which released: “TG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23rd Congress of the European …” on June 15, 2018, also Seekingalpha.com with their article: “TG Therapeutics: An Immunology Powerhouse” published on June 14, 2018, Globenewswire.com published: “TG Therapeutics, Inc. Appoints Adam Waldman as Chief Commercial Officer” on June 04, 2018. More interesting news about TG Therapeutics, Inc. (NASDAQ:TGTX) were released by: Nasdaq.com and their article: “TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K …” published on June 18, 2018 as well as Streetinsider.com‘s news article titled: “TG Therapeutics (TGTX) Reports Updated Results from Ongoing Phase 2 Study of Ublituximab in Patients with Multiple …” with publication date: June 18, 2018.

TG Therapeutics, Inc. (NASDAQ:TGTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.